PB Ratio: 5.10
Is the P/B ratio high or low?
The P/B ratio of 5.10 is 34% below its 5-year average of 7.77, near the low end of its 5-year range (3.96–15.13).
10.48% above its 12-month average of 4.62.
EW PB Ratio Chart
EW Average PB Ratio Chart
EW Current vs Average PB Ratio Chart
EW PB Ratio Metrics
PB RATIO
5.10
PB RATIO AVG TTM
4.62
PB RATIO AVG 3Y
5.68
PB RATIO AVG 5Y
7.77
PB RATIO AVG 10Y
9.17
PB RATIO AVG 15Y
8.34
PB RATIO AVG 20Y
7.42
CURRENT VS TTM AVG
+10.48%
CURRENT VS 3Y AVG
-10.22%
CURRENT VS 5Y AVG
-34.34%
CURRENT VS 10Y AVG
-44.38%
CURRENT VS 15Y AVG
-38.84%
CURRENT VS 20Y AVG
-31.28%
EW Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 5.10 | 4.62 | 5.68 | 7.77 |
| Cencora, Inc. (COR)vs › | $55.67B | 16.45 | 35.10 | 66.99 | 114.25 |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | N/A | 10.98 | 10.12 | 7.19 |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 1.81 | 1.73 | 1.97 | 2.08 |
| Humana Inc. (HUM)vs › | $46.08B | 2.49 | 1.67 | 2.29 | 2.90 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 28.59 | 32.91 | 30.48 | 44.79 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 2.17 | 2.35 | 3.19 | 3.52 |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 2.56 | 5.43 | 5.53 | 4.82 |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 5.42 | 5.55 | 6.10 | 6.95 |
| Medline Inc. (MDLN)vs › | $32.87B | 2.84 | 3.15 | 3.15 | 3.15 |
P/B vs. its own history
At 5.10, P/B is cheaper than usual, sitting higher than 30% of its 20-year history.
20-year low
2.94
median
7.02
20-year high
15.13
Book Value Analysis
P/B Ratio
5.10
Market Price / Book Value per Share
PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
PB Ratio FAQ
- What is the P/B ratio for Edwards Lifesciences Corporation (EW)?
- The P/B ratio for EW stock is 5.10.
- Is Edwards Lifesciences Corporation's P/B ratio high or low?
- The P/B ratio of 5.10 is 34% below its 5-year average of 7.77, near the low end of its 5-year range (3.96–15.13).
- What is the TTM average P/B ratio for Edwards Lifesciences Corporation (EW)?
- The TTM average P/B ratio for EW stock is 4.62.
- What is the 3Y average P/B ratio for Edwards Lifesciences Corporation (EW)?
- The 3Y average P/B ratio for EW stock is 5.68.
- What is the 5Y average P/B ratio for Edwards Lifesciences Corporation (EW)?
- The 5Y average P/B ratio for EW stock is 7.77.
- What is the 10Y average P/B ratio for Edwards Lifesciences Corporation (EW)?
- The 10Y average P/B ratio for EW stock is 9.17.
- What is the 15Y average P/B ratio for Edwards Lifesciences Corporation (EW)?
- The 15Y average P/B ratio for EW stock is 8.34.
- What is the 20Y average P/B ratio for Edwards Lifesciences Corporation (EW)?
- The 20Y average P/B ratio for EW stock is 7.42.
EW PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-26 | 5.10 |
| 2026-06-25 | 5.04 |
| 2026-06-24 | 5.04 |
| 2026-06-23 | 4.89 |
| 2026-06-22 | 4.83 |
| 2026-06-18 | 4.91 |
| 2026-06-17 | 4.87 |
| 2026-06-16 | 4.98 |
| 2026-06-15 | 4.85 |
| 2026-06-12 | 4.79 |
| 2026-06-11 | 4.82 |
| 2026-06-10 | 4.83 |
| 2026-06-09 | 4.92 |
| 2026-06-08 | 4.83 |
| 2026-06-05 | 4.83 |
| 2026-06-04 | 4.92 |
| 2026-06-03 | 4.84 |
| 2026-06-02 | 4.93 |
| 2026-06-01 | 4.96 |
| 2026-05-29 | 4.86 |
| 2026-05-28 | 4.83 |
| 2026-05-27 | 4.86 |
| 2026-05-26 | 4.92 |
| 2026-05-22 | 4.82 |
| 2026-05-21 | 4.68 |
| 2026-05-20 | 4.67 |
| 2026-05-19 | 4.62 |
| 2026-05-18 | 4.63 |
| 2026-05-15 | 4.58 |
| 2026-05-14 | 4.57 |
| 2026-05-13 | 4.58 |
| 2026-05-12 | 4.48 |
| 2026-05-11 | 4.34 |
| 2026-05-08 | 4.50 |
| 2026-05-07 | 4.65 |
| 2026-05-06 | 4.68 |
| 2026-05-05 | 4.67 |
| 2026-05-04 | 4.69 |
| 2026-05-01 | 4.73 |
| 2026-04-30 | 4.70 |
| 2026-04-29 | 4.57 |
| 2026-04-28 | 4.63 |
| 2026-04-27 | 4.70 |
| 2026-04-24 | 4.74 |
| 2026-04-23 | 4.49 |
| 2026-04-22 | 4.59 |
| 2026-04-21 | 4.49 |
| 2026-04-20 | 4.58 |
| 2026-04-17 | 4.56 |
| 2026-04-16 | 4.45 |
| 2026-04-15 | 4.40 |
| 2026-04-14 | 4.40 |
| 2026-04-13 | 4.40 |
| 2026-04-10 | 4.38 |
| 2026-04-09 | 4.45 |
| 2026-04-08 | 4.60 |
| 2026-04-07 | 4.55 |
| 2026-04-06 | 4.57 |
| 2026-04-02 | 4.56 |
| 2026-04-01 | 4.57 |
| 2026-03-31 | 4.51 |
| 2026-03-30 | 4.47 |
| 2026-03-27 | 4.47 |
| 2026-03-26 | 4.62 |
| 2026-03-25 | 4.65 |
| 2026-03-24 | 4.60 |
| 2026-03-23 | 4.62 |
| 2026-03-20 | 4.64 |
| 2026-03-19 | 4.64 |
| 2026-03-18 | 4.65 |
| 2026-03-17 | 4.74 |
| 2026-03-16 | 4.70 |
| 2026-03-13 | 4.60 |
| 2026-03-12 | 4.76 |
| 2026-03-11 | 4.79 |
| 2026-03-10 | 4.83 |
| 2026-03-09 | 4.74 |
| 2026-03-06 | 4.59 |
| 2026-03-05 | 4.72 |
| 2026-03-04 | 4.80 |
| 2026-03-03 | 4.80 |
| 2026-03-02 | 4.91 |
| 2026-02-27 | 4.87 |
| 2026-02-26 | 4.83 |
| 2026-02-25 | 4.69 |
| 2026-02-24 | 4.73 |
| 2026-02-23 | 4.73 |
| 2026-02-20 | 4.58 |
| 2026-02-19 | 4.53 |
| 2026-02-18 | 4.53 |
| 2026-02-17 | 4.50 |
| 2026-02-13 | 4.35 |
| 2026-02-12 | 4.39 |
| 2026-02-11 | 4.55 |
| 2026-02-10 | 4.42 |
| 2026-02-09 | 4.41 |
| 2026-02-06 | 4.52 |
| 2026-02-05 | 4.48 |
| 2026-02-04 | 4.58 |
| 2026-02-03 | 4.71 |
| 2026-02-02 | 4.74 |
| 2026-01-30 | 4.67 |
| 2026-01-29 | 4.68 |
| 2026-01-28 | 4.70 |
| 2026-01-27 | 4.80 |
| 2026-01-26 | 4.84 |
| 2026-01-23 | 4.80 |
| 2026-01-22 | 4.85 |
| 2026-01-21 | 4.89 |
| 2026-01-20 | 4.79 |
| 2026-01-16 | 4.84 |
| 2026-01-15 | 4.85 |
| 2026-01-14 | 4.77 |
| 2026-01-13 | 4.81 |
| 2026-01-12 | 4.76 |
| 2026-01-09 | 4.89 |
| 2026-01-08 | 4.85 |
| 2026-01-07 | 4.87 |
| 2026-01-06 | 4.93 |
| 2026-01-05 | 4.83 |
| 2026-01-02 | 4.90 |
| 2025-12-31 | 4.89 |
| 2025-12-30 | 4.95 |
| 2025-12-29 | 4.99 |
| 2025-12-26 | 4.98 |
| 2025-12-24 | 4.95 |
| 2025-12-23 | 4.95 |
| 2025-12-22 | 4.97 |
| 2025-12-19 | 4.92 |
| 2025-12-18 | 4.87 |
| 2025-12-17 | 4.87 |
| 2025-12-16 | 4.90 |
| 2025-12-15 | 4.79 |
| 2025-12-12 | 4.77 |
| 2025-12-11 | 4.83 |
| 2025-12-10 | 4.82 |
| 2025-12-09 | 4.78 |
| 2025-12-08 | 4.84 |
| 2025-12-05 | 4.95 |
| 2025-12-04 | 4.92 |
| 2025-12-03 | 4.82 |
| 2025-12-02 | 4.86 |
| 2025-12-01 | 4.89 |
| 2025-11-28 | 4.97 |
| 2025-11-26 | 4.98 |
| 2025-11-25 | 4.98 |
| 2025-11-24 | 4.86 |
| 2025-11-21 | 4.89 |
| 2025-11-20 | 4.83 |
| 2025-11-19 | 4.94 |
| 2025-11-18 | 4.82 |
| 2025-11-17 | 4.86 |
| 2025-11-14 | 4.95 |
| 2025-11-13 | 4.94 |
| 2025-11-12 | 4.91 |
| 2025-11-11 | 4.89 |
| 2025-11-10 | 4.83 |
| 2025-11-07 | 4.79 |
| 2025-11-06 | 4.73 |
| 2025-11-05 | 4.75 |
| 2025-11-04 | 4.69 |
| 2025-11-03 | 4.63 |
| 2025-10-31 | 4.60 |
| 2025-10-30 | 4.65 |
| 2025-10-29 | 4.61 |
| 2025-10-28 | 4.58 |
| 2025-10-27 | 4.51 |
| 2025-10-24 | 4.24 |
| 2025-10-23 | 4.27 |
| 2025-10-22 | 4.28 |
| 2025-10-21 | 4.24 |
| 2025-10-20 | 4.20 |
| 2025-10-17 | 4.16 |
| 2025-10-16 | 4.05 |
| 2025-10-15 | 4.07 |
| 2025-10-14 | 4.09 |
| 2025-10-13 | 4.07 |
| 2025-10-10 | 4.12 |
| 2025-10-09 | 4.19 |
| 2025-10-08 | 4.22 |
| 2025-10-07 | 4.28 |
| 2025-10-06 | 4.27 |
| 2025-10-03 | 4.30 |
| 2025-10-02 | 4.27 |
| 2025-10-01 | 4.25 |
| 2025-09-30 | 4.34 |
| 2025-09-29 | 4.30 |
| 2025-09-26 | 4.25 |
| 2025-09-25 | 4.20 |
| 2025-09-24 | 4.16 |
| 2025-09-23 | 4.16 |
| 2025-09-22 | 4.11 |
| 2025-09-19 | 4.15 |
| 2025-09-18 | 4.16 |
| 2025-09-17 | 4.19 |
| 2025-09-16 | 4.19 |
| 2025-09-15 | 4.24 |
| 2025-09-12 | 4.32 |
| 2025-09-11 | 4.35 |
| 2025-09-10 | 4.36 |
| 2025-09-09 | 4.45 |
| 2025-09-08 | 4.47 |
| 2025-09-05 | 4.51 |
| 2025-09-04 | 4.51 |
| 2025-09-03 | 4.53 |
| 2025-09-02 | 4.56 |
| 2025-08-29 | 4.53 |
| 2025-08-28 | 4.53 |
| 2025-08-27 | 4.51 |
| 2025-08-26 | 4.53 |
| 2025-08-25 | 4.51 |
| 2025-08-22 | 4.56 |
| 2025-08-21 | 4.52 |
| 2025-08-20 | 4.54 |
| 2025-08-19 | 4.40 |
| 2025-08-18 | 4.37 |
| 2025-08-15 | 4.36 |
| 2025-08-14 | 4.36 |
| 2025-08-13 | 4.33 |
| 2025-08-12 | 4.29 |
| 2025-08-11 | 4.36 |
| 2025-08-08 | 4.37 |
| 2025-08-07 | 4.34 |
| 2025-08-06 | 4.38 |
| 2025-08-05 | 4.60 |
| 2025-08-04 | 4.65 |
| 2025-08-01 | 4.60 |
| 2025-07-31 | 4.60 |
| 2025-07-30 | 4.71 |
| 2025-07-29 | 4.67 |
| 2025-07-28 | 4.56 |
| 2025-07-25 | 4.64 |
| 2025-07-24 | 4.40 |
| 2025-07-23 | 4.46 |
| 2025-07-22 | 4.43 |
| 2025-07-21 | 4.44 |
| 2025-07-18 | 4.44 |
| 2025-07-17 | 4.42 |
| 2025-07-16 | 4.42 |
| 2025-07-15 | 4.46 |
| 2025-07-14 | 4.54 |
| 2025-07-11 | 4.53 |
| 2025-07-10 | 4.57 |
| 2025-07-09 | 4.48 |
| 2025-07-08 | 4.43 |
| 2025-07-07 | 4.45 |
| 2025-07-03 | 4.46 |
| 2025-07-02 | 4.47 |
| 2025-07-01 | 4.48 |
| 2025-06-30 | 4.54 |
| 2025-06-27 | 4.54 |
| 2025-06-26 | 4.48 |
| 2025-06-25 | 4.47 |
| 2025-06-24 | 4.40 |
| 2025-06-23 | 4.37 |
| 2025-06-20 | 4.28 |
| 2025-06-18 | 4.29 |
| 2025-06-17 | 4.25 |
| 2025-06-16 | 4.34 |
| 2025-06-13 | 4.36 |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian